Two novel oral antiviral agents were granted emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in late December 2021. Although it is named after Thor’s hammer, Mjölnir, molnupiravir was given a last place (4th line) recommendation by the National Institutes of Health (NIH) COVID-19 Treatment Guideline Panel. What gives?
Guest Authors: Amanda Applegate, PharmD, BCACP and Mary Beth Dameron, PharmD, BCACP
Music by Good Talk
Sweetening the Deal: Effects of SGLT-2 Inhibitors on Kidney Disease Progression
Opioid Safety and Overdose Prevention
Eleven Things Every Clinician Should Know About the “Egregious Eleven”
HIP-HIP-HOPE-3! Expanded role for statin therapy for primary prevention
Liraglutide: the new LEADER for second line therapy in diabetes management?
The EAGLE has Landed! Reassuring the Safety and Efficacy of Drugs for Smoking Cessation in Mental Illness
Preventing Weight Gain - Recommending Behavior Change in Young Adults
What’s the story, H. pylori? New regimens in the toolbox?
PATHWAY-2: Does the road lead to spironolactone for resistant hypertension?
Does Coenzyme Q10 Have the ENERGY to Change Heart Failure Therapy?
Beyond Slip, Slop, Slap, and Wrap: Vitamin B3 for Skin Cancer Prevention
Lixisenatide and Cardiovascular Outcomes: The Burden of Proof
Drug Treatment for Agitation in Alzheimer’s Disease: A Conundrum
Crossing the Periprocedural Bridge in Patients with Atrial Fibrillation
Reconsidering Strategies for Insulin Intensification
TEXT ME — Text Messaging to Promote Behavior Change
Pulling Ahead After a SPRINT – Evidence for Lower Blood Pressure Goals
Televised Medical Talk Shows – Is There Truth in Edutainment?
Preventing Gestational Diabetes with Myo-Inositol: Ready for Prime Time?
An Aspirin a Day to Prevent Colon CA
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive